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Summary  Infective  endocarditis  (IE)  is  a  life-threatening  complication  that  may  impair  signi-
ﬁcantly the  long-term  prognosis  of  patients  with  cardiac  disease.  The  proﬁle  of  IE  has  changed
over recent  decades,  with  a  decreasing  prevalence  of  rheumatic  fever  and  increasing  survival  of
patients with  congenital  heart  disease  (CHDs).  Given  the  high  rates  of  morbidity  and  mortality,
and based  on  previous  experimental  studies,  antibiotic  prevention  of  IE  has  long  been  recom-
mended for  at-risk  groups.  Serial  revised  guidelines  for  prophylaxis  have  been  published  over
the years.  The  most  recent  recommendations  differ  dramatically  from  previous  guidelines  and
provide new  insights  into  the  prophylaxis  of  IE.  Emphasis  is  put  on  oral  activities  (particularly
brushing  teeth)  as  both  buccal  and  skin  hygiene  may  present  the  greatest  threats  for  individuals
at-risk of  IE.  Signiﬁcant  limitations  in  both  at-risk  patients  and  procedures  result  in  a  potential
and substantial  change  in  the  practice  of  clinicians  and  raise  concerns  about  the  safety  and
reliability of  these  new  recommendations  for  patients  with  CHD.
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Résumé  L’endocardite  infectieuse  (EI)  est  une  complication  grave  potentiellement  létale
susceptible  de  grever  le  pronostic  à  long  terme  des  patients  porteurs  d’une  pathologie  car-
diaque. Le  proﬁl  actuel  de  l’EI  d’est  modiﬁé  depuis  les  dernières  décennies,  secondairement  à
la régression  du  rhumatisme  articulaire  aigu,  et  l’augmentation  de  la  survie  des  patients  por-
teurs de  cardiopathie  congénitale.  Face  au  risque  important  de  morbidité  et  mortalité  de  l’EI
et sur  la  base  d’études  expérimentales,  la  prophylaxie  antibiotique  de  l’EI  a  été  recommandée
pendant de  nombreuses  années  pour  les  groupes  à  haut  risque.  Plusieurs  révisions  des  consignes
de prophylaxie  ont  été  émises  au  cours  du  temps.  Les  plus  récentes  diffèrent  des  précédentes
de fac¸on  notable  et  supposent  une  modiﬁcation  radicale  des  principes  de  prévention  de  l’EI.  Ces
nouvelles recommandations  arguent  que  les  activités  de  la  vie  courante  concernant  l’hygiène
buccale et  cutanée  représentent  les  situations  où  le  risque  d’EI  est  le  plus  important  pour
l’individu.  Ainsi  la  réduction  drastique  à  la  fois  des  groupes  et  des  procédures  à  risque  conduisant
à un  changement  radical  de  pratique  des  cliniciens,  conduit  également  à  s’interroger  sur  sa  ﬁa-
bilité et  les  conditions  de  sécurité  de  son  application  pour  les  patients  porteurs  de  cardiopathie
congénitale.
© 2012  Publié  par  Elsevier  Masson  SAS.
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The  incidence  of  infective  endocarditis  (IE)  is  reported  to
vary  from  1.5  to  six  cases  per  100,000  persons  per  year  in
adults.  The  percentage  of  IE  in  congenital  heart  diseases
(CHDs)  has  increased  relative  to  the  decrease  in  rheumatic
fever  [1].  IE  is  supposed  to  occur  much  less  frequently  in  chil-
dren.  However,  more  complex  surgical  CHD  procedures  with
implanted  material  and  prostheses  and/or  residual  lesions
are  likely  to  result  in  ongoing  IE  occurrence.  Moreover,  more
children  can  currently  reach  adulthood,  even  with  complex
CHD,  so  the  cohort  of  patients  with  CHD  is  increasing.  The
relative  incidence  of  IE  is  therefore  likely  to  remain  the  same
or  even  increase  in  paediatric  and  adult  patients  with  CHD.
An  IE  diagnosis  and  its  sequelae  are  reported  to  account  for
4—5%  of  in-hospital  admissions  of  patients  with  CHD  and  a
2.3%  frequency  of  adult-onset  IE  in  adults  with  CHD.  As  a
result,  IE  represents  a  lifelong  risk  in  these  patients.  Vari-
ous  factors  may  impact  on  the  level  of  risk,  such  as  the  type
of  underlying  cardiac  disease,  the  presence  of  prosthetic
material  and  the  microbial  causal  agent.
Prognosis of infective endocarditis (IE)
Despite  improvement  in  early  diagnosis,  management,
microbial  diagnosis  and  therapeutics  and  even  surgical  tech-
niques,  the  morbidity  and  mortality  rates  of  IE  remain
signiﬁcant  [2];  the  mortality  rate  varies  from  10—15%.
Therefore,  IE  represents  a  life-threatening,  ongoing  compli-
cation  that  may  impair  long-term  outcomes  in  patients  with
CHD  [3].
Data  from  the  literature  have  shown  IE  to  be  less  severe
in  children,  which  might  be  due  to  the  higher  proportion  of
right-sided  IE  in  patients  with  CHD,  particularly  in  those  with
a  ventricular  septal  defect  (VSD)-located  infection  [4—7].
In  a  recent  review  of  IE  in  CHD,  Knirsch  et  al.  reported
a  10%  overall  mortality  rate,  a  14%  surgical  mortality  rate
and  a  recurrence  rate  of  inferior  than  3%  [8].  Besides  early
a
o
r
eortality  and  morbidity,  IE  may  also  impact  on  the  long-
erm  functional  status  of  patients  with  CHD,  considering  that
any  of  them  were  asymptomatic  before  the  IE  occurred
9].  In  our  own  long-term  experience  with  IE  in  adult  and
aediatric  CHD  patients,  more  than  50%  of  deaths  in  this
ohort  can  be  directly  related  to  IE,  while  others  are  due  to
ither  IE  sequelae  management  or  CHD  outcomes,  regardless
f  the  IE  episode  [2].
athogenesis
hree  major  components  must  interact  to  result  in  IE:
the  underlying  cardiac  lesion  and  endocardial  damage;
the  circumstances  leading  to  signiﬁcant  lesions  of  the
mucosa,  which  are  susceptible  to  bacteraemia;
the  volume  of  the  microbial  inoculum  and  virulence  of  the
bacterial  agent.
The  key  factor  for  IE  to  develop  is  ﬁrstly  endocardial
amage.  This  lesion  allows  ﬁbrinogen  deposits,  platelet
ggregation  and  thrombi  formation.  Interactions  with  cir-
ulating  pathogens  may  promote  microbial  adherence  to
hrombi,  resulting  in  the  development  of  an  IE-speciﬁc  lesion
so-called  vegetation).  A  prosthetic  surface  is  particularly
xposed  to  ﬁbrinogen  binding  and  also  promotes  turbulence
f  blood  ﬂow  and  endothelial  injuries,  making  prosthetic
aterials  high-risk  factors  for  IE.
Given  the  prognosis,  morbidity  and  high  cost  of  manage-
ent  of  IE,  prophylaxis  has  long  been  recommended  in  an
ttempt  to  minimize  the  incidence  of  IE.  Guidelines  have
een  published  and  revised  over  the  years,  to  deﬁne  the
nderlying  CHD  level  of  risk,  the  procedures  and  events
hat  carry  the  highest  risk  and  the  protocols  for  antibiotic
revention  of  IE,  thereby  identifying  ‘who’  should  beneﬁt
rom  prophylaxis,  ‘when’  to  adequately  apply  prophylaxis
nd  ‘how’  to  administer  prophylaxis.  Nevertheless,  IE  still
ccurs  and  its  incidence  is  not  lessening  signiﬁcantly,  which
aises  the  question  of  whether  non-compliance  or  lack  of
fﬁcacy  (or  both)  is  implicated.
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As  yet,  no  randomized  study  has  been  conducted  to  elu-
idate  whether  or  not  IE  prophylaxis  should  be  applied,  and
f  it  should,  then  to  whom  and  when  it  should  be  applied.
ockhart  et  al.  [10]  conducted  a  prospective,  comparative
tudy  designed  to  compare  subjects  who  received  amox-
cillin  before  tooth  extraction  with  subjects  who  had  no
ntibiotics  and  were  given  a  placebo  before  the  dental
rocedure.  The  authors  showed  that  bacteraemia  was  less
requent  in  the  amoxicillin  group  (33%)  than  in  the  placebo
roup  (84%)  but  this  result  does  not  demonstrate  that  IE
ould  have  occurred.  Recommendations  were  based  on
xperimental  animal  studies  that  previously  demonstrated
he  efﬁcacy  of  antibiotics  in  preventing  IE  when  adminis-
ered  before  bacteria  inoculation  [11], and  also  on  medical
ractice  and  experience  [12]. Conversely,  most  published
ata  have  reported  that  IE  can  still  occur  despite  prophylaxis
eing  applied  according  to  current  recommendations.
Thus,  recommendations  for  IE  prophylaxis  have  eased
ramatically  over  the  years.  Based  on  case-control  studies,
xpert  opinion  and  daily  practice,  the  last  revised  Amer-
can  Heart  Association  (AHA)  guidelines  published  in  2007
esulted  in  a  drastic  reduction  and  limitation  of  the  cardiac
iseases  and  procedures  in  which  IE  prophylaxis  is  indicated
13].
ationale for revised recommendations
or infective endocarditis (IE) prophylaxis
everal  main  points  have  led  to  the  new  expert  consensus  in
he  ﬁeld  of  IE  prophylaxis.
First,  ‘IE  is  much  more  likely  to  result  from  frequent
xposure  to  random  bacteraemia  associated  with  daily
ctivities  than  from  bacteraemia  caused  by  a  dental,  gas-
rointestinal  tract  or  genitourinary  tract  procedure’.  IE
ccurs  rarely  and  is  unlikely  to  impair  signiﬁcantly  the  over-
ll  prognosis  of  patients.  The  ratio  of  the  number  of  treated
E  cases  to  the  number  of  cases  undergoing  prophylaxis  is
ar  too  low  to  support  routine  prevention  of  IE.  ‘Prophy-
axis  may  prevent  an  exceedingly  small  number  of  cases  of
E,  if  any,  in  individuals  who  undergo  a  dental,  gastroin-
estinal  tract  or  genitourinary  tract  procedure’.  However
o  mention  exists  about  the  costs  due  to  IE  management
hospitalization,  antibiotics,  techniques  for  anatomical  and
icrobial  diagnosis,  iterative  surgeries,  long-term  follow-
p,  management  and  complications)  or  about  patients’  vital
nd  functional  prognosis.  The  low  cost  of  prophylaxis  has
o  be  weighted  against  the  high  costs  of  IE  diagnosis  and
reatment.
The  second  and  most  important  point  is  that  procedures
re  less  likely  to  cause  IE  than  daily  activities  and  poor
atient  hygiene.  Que  and  Moreillon  [14]  assessed  the  the-
retical  cumulative  bacteraemia  resulting  from  daily  oral
ctivities  such  as  brushing  teeth  or  chewing  and  concluded
hat  1-year  everyday  bacteraemia  is  six  million  times  greater
han  that  associated  with  1-year  bacteraemia  due  to  a  den-
al  extraction.  Thus,  it  is  not  clear  whether  daily-activity
elated  bacteraemia  could  reach  the  cut-off  inoculum
olume  to  seed  the  cardiac  tissue  [15]. Therefore,  the
xperts  stated  that  ‘Maintenance  of  optimal  oral  health  and
ygiene  may  reduce  the  incidence  of  bacteraemia  from  daily
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ctivities  and  is  more  important  than  prophylactic  antibi-
tics  for  a  dental  procedure  to  reduce  the  risk  of  IE’.
Another  point  is  that  some  patients  who  undergo  dental
rocedures  have  an  underlying  cardiac  disease  that  has  not
een  recognized.  We  observed  such  cases  in  our  experience
f  IE  in  CHD,  where  the  underlying  diseases  were  mostly
inor  valvular  lesions,  such  as  aortic  bicuspidia  or  mitral
alve  prolapse  (MVP).  These  patients  with  unrecognized  CHD
ccounted  for  about  15%  of  our  cases.
Lastly,  the  experts  considered  antibiotic  side  effects,
ncluding  microbial-induced  resistance  and  anaphylaxis.
owever,  no  report  has  been  published  about  resistance  due
o  one-dose  amoxicillin  and  no  case  has  been  reported  of
eath  due  to  antibiotic-induced  anaphylaxis,  whereas  mor-
ality  due  to  IE  is  still  signiﬁcant  and  widely  reported.
Finally,  the  revised  recommendations  were  also  based  on
he  lack  of  a  controlled  randomized  study  to  prove  the  efﬁ-
acy  of  IE  prophylaxis.  The  number  of  patients  necessary  to
onduct  a  controlled,  randomized  trial  to  assess  the  effec-
iveness  of  IE  prophylaxis  has  been  estimated  to  be  superior
o  6000  patients  per  group,  which  has  discouraged  centres
rom  initiating  such  a  study  [12,16].
nderlying congenital heart disease (CHD)
n  previous  recommendations,  CHDs  were  classiﬁed  into
igh-risk,  moderate-risk  or  mild-risk  groups.  Recent  guide-
ines  resulted  in  a  drastic  reduction  in  the  target  CHDs  for
E  prophylaxis  and  suppression  of  the  CHD  classiﬁcation  into
t  high,  moderate  or  mild-risk  for  IE,  assuming  that  only
atients  in  the  previously-named  ‘high-risk’  group  should
eceive  IE  prophylaxis.  The  other  CHDs,  previously  in  the
oderate-risk  or  mild-risk  groups,  are  no  longer  targets  for
E  prophylaxis  [13,17,18].
In summary,  cardiac  conditions  associated  with  the  high-
st  risk  of  adverse  outcome  from  endocarditis,  for  which
rophylaxis  with  dental  procedures  is  reasonable,  include
13]:
prosthetic  cardiac  valve  or  prosthetic  material  used  for
cardiac  valve  repair;
previous  IE;
unrepaired  cyanotic  CHD,  including  palliative  shunts  and
conduits;
completely  repaired  congenital  heart  defect  with  pros-
thetic  material  or  device,  whether  placed  by  surgery  or  by
catheter  intervention,  during  the  ﬁrst  6  months  after  the
procedure.  In  this  case,  prophylaxis  is  reasonable  because
endothelialization  of  prosthetic  material  occurs  within
6  months  after  the  procedure;
repaired  CHD  with  residual  defects  at  the  site  or  adja-
cent  to  the  site  of  a  prosthetic  patch  or  prosthetic  device
(which  inhibit  endothelialization);
cardiac  transplantation  recipients  who  develop  cardiac
valvulopathy.
Except  for  the  conditions  listed  above,  antibiotic  pro-
hylaxis  is  no  longer  recommended  for  any  other  form  of
HD.
It  is  well  recognized  that  surgical  repair  may  nullify  the
ifetime  risk  of  IE,  provided  that  neither  residual  lesion  nor
rosthetic  material  is  present.  In  fact,  only  a  few  CHDs  can
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be  completely  cured;  some  kind  of  residual  lesion  often
persists  (residual  shunt,  valve  anomaly,  etc.)  or  prosthetic
materials  are  implanted  (valvular  prosthesis,  tubes,  anasto-
mosis,  patches).
Considering  that  high-velocity  and  turbulent  ﬂow  are
more  likely  to  generate  endothelial  lesions  and  promote  IE,
risk  varies  consecutively  according  to  the  underlying  car-
diac  lesions,  although  the  guidelines  no  longer  attach  any
importance  to  this  assessment.
Lastly,  some  IE  episodes  were  reported  in  patients  who
underwent  interventional  procedures,  which  raised  the
question  of  whether  these  cases  should  receive  prophylaxis.
Regarding  cyanotic  unrepaired  or  palliated  CHD,  there  is
a  common  consensus  for  IE  prevention,  as  well  for  patients
who  have  experienced  a  previous  IE  episode.  These  CHDs  are
considered  at  highest  risk  for  IE.
IE  prevention  is  no  longer  recommended  in  repaired  CHD,
in  case  of  no  residual  lesion  [13]  but  prophylaxis  should  be
applied  within  the  ﬁrst  6  months  after  repair,  while  endothe-
lialization  develops,  particularly  after  patch  closure  of  a
VSD.  However,  any  residual  shunt  or  associated  lesion,  such
as  aortic  insufﬁciency,  will  justify  lifelong  IE  prophylaxis,
given  that  endothelialization  cannot  occur.  This  assessment
seems  to  be  in  discrepancy  with  the  same  native  unrepaired
lesion  (i.e.  VSD  or  aortic  regurgitation).
A  review  by  Knirsch  et  al.  aimed  to  estimate  the  mean
frequency  of  repaired  and  unrepaired  CHD  in  an  IE  series  [8].
The  author  showed  that  IE  is  a  lifetime  risk  for  repaired,  non-
operated  and  palliated  CHD.  Aortic  and  mitral  valves  are  the
most  frequent  targets  for  IE,  including  unoperated  and  non-
haemodynamically  signiﬁcant  valvulopathies.  If  unrepaired,
VSD  is  the  most  frequent  CHD  associated  with  IE.  The  cumu-
lative  incidence  of  IE  over  a  25-year  follow-up  after  surgical
repair  (or  interventional  procedure)  is  as  follows,  according
to  the  CHD:
• 1.3%  for  tetralogy  of  Fallot;
• 2.7%for  VSD;
• 2.8%  for  primum-type  atrial  septal  defect  (ASD);
• 3.5%  for  coarctation  of  aorta;
• 13%  for  aortic  valve  stenosis;
• 0%  for  ostium  secundum  ASD,  patent  ductus  arteriosus
(PDA)  and  pulmonary  valve  stenosis.
A  30-year  follow-up  demonstrated  a  cumulative  IE  inci-
dence  of  4.0%  for  transposition  of  the  great  arteries,  5.3%
for  pulmonary  atresia  with  intact  ventricular  septum  and
up  to  6.4%  for  VSD  [19]. Risk  is  evidently  increased  by  any
prosthetic  material  and  devices.
Procedures
Endocardial  lesion  is  the  primary  target  for  microbial  adher-
ence.  Therefore,  any  cause  of  signiﬁcant  bacteraemia  will
potentially  be  the  initial  factor  in  the  occurrence  of  IE.  In
1909,  Horder  [20]  observed  a  link  between  mouth  infection
and  IE.  Tooth  extraction  was  later  shown  to  induce  bac-
teraemia.  Moreover,  the  microbial  agents  most  susceptible
to  causing  IE  belong  to  the  Streptococcus  group  from  oral
origin.  Indeed,  any  procedure  that  could  potentially  cause
bacteraemia  was  thought  to  represent  a  potential  route  of
entry.  Dental  procedure  was  the  leading  target  for  antibiotic
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rophylaxis;  animal  experiments  demonstrated  the  effec-
iveness  of  antibiotics  in  preventing  the  development  of
E  after  experimental  inoculation  of  bacteria  [11]. Based
n  these  experimental  studies  and  on  common  practice  in
atients  who  were  diagnosed  with  IE  within  several  weeks
fter  an  unprotected  dental  procedure,  protocols  for  pre-
ention  of  IE  have  long  been  applied  to  minimize  risk  and
revent  bacteraemia  and  subsequent  development  of  IE.
IE  can  occur  despite  an  adequate  current  protocol  for
E  prevention  having  been  applied  but  most  of  the  time-
etailed  data  about  antibiotic  administration  are  lacking.
mperiale  et  al.  showed  that  only  13%  of  patients  who
xperienced  IE  after  an  unprotected  dental  procedure  had
eceived  prophylaxis  compared  with  63%  of  matched  con-
rols  who  had  no  IE  [21].
Conversely,  not  only  dental  procedures,  but  also  any
ther  procedure  susceptible  to  damaging  the  mucosa  was
upposed  to  carry  the  same  risk.  In  particular,  digestive,  uri-
ary  or  bronchial  procedures  were  also  involved  in  previous
ecommendations  for  IE  prophylaxis.
On  the  basis  of  a  Cochrane  review  that  showed  little  evi-
ence  to  support  the  published  guidelines  [22], revisited
uidelines  have  completely  changed  the  previous  assess-
ents.  Indeed,  no  randomized,  controlled  trial  exists  to
emonstrate  the  efﬁcacy,  reliability  or  safety  of  antibiotics
or  the  prevention  of  IE.  Such  a  study  is  still  questionable
ecause  of  ethical  issues  and  the  prohibitively  high  number
f  enrolled  patients  required  per  group.
It  is  known  that  bacteraemia  is  more  likely  to  result  from
aily  activities  such  as  chewing,  brushing  teeth  and  using
ater  irrigation  devices  for  tooth  cleaning  than  from  dental
rocedures  [15]. Experts  have  identiﬁed  oral  hygiene  as  the
ost  important  endpoint  for  bacterial  prevention  of  IE.
Clinical  reports  and  series  often  fail  to  prove  the  link
etween  IE  and  a  previous  procedure.  The  causative  event
an  only  be  retrieved  in  one  third  of  cases.  Even  in  case
f  close  temporal  association  between  a  precedent  event
r  procedure  and  onset  of  IE,  it  is  still  hardly  possible  to
etermine  whether  the  bacteraemia  was  induced  by  the
rocedure  or  by  other  daily  activities  or  poor  oral  hygiene
12].
The  new  guidelines  recommend  prophylaxis  for  any  pro-
edure  that  may  alter  the  gingival  tissue,  the  periapical
egion  or  induce  perforation  of  oral  mucosa  (i.e.  biop-
ies,  suture  removal,  placement  of  orthodontic  bands,  tooth
xtractions  and  periodontal  procedures).  Conversely,  the
ollowing  procedures  and  events  do  not  need  prophylaxis:
outine  local  anaesthetic  injections  through  non-infected
issue,  taking  dental  radiographs,  placement  of  remov-
ble  prosthodontic  or  orthodontic  appliances,  adjustment
f  orthodontic  appliances,  placement  of  orthodontic  brack-
ts,  shedding  of  deciduous  teeth  and  bleeding  from  trauma
o  the  lips  or  oral  mucosa  [13].
Prophylaxis  is  no  longer  recommended  for  any  other
on-dental  procedures.  Therefore,  digestive  endoscopic
anipulations  or  procedures  in  the  respiratory  tract  do  not
equire  antibiotic  administration,  even  in  groups  at  high-
isk,  unless  ongoing  tissue  infection  is  recognized.  This
ssessment  also  includes  skin  tissue;  the  AHA  guidelines
rovide  advice  against  body  piercing  but  give  no  clear
ecommendation.  For  patients  with  the  highest  risk  of  IE
ho  undergo  a  procedure  that  involves  infected  skin  or
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usculoskeletal  tissue,  the  therapeutic  regimen  adminis-
ered  for  treatment  of  the  infection  should  contain  an  agent
ctive  against  Staphylococcus  and  beta-haemolytic  Strepto-
occus  [23].
Guidelines  currently  focus  on  daily  mouth  and  skin
ygiene.  In  a  double-blind,  placebo-controlled  study,  Lock-
art  et  al.  assessed  bacteraemia  in  290  subjects  randomized
o  tooth  brushing  or  single  tooth  extraction  with  amoxi-
illin  prophylaxis  or  single  tooth  extraction  with  identical
lacebo  [24]. The  cumulative  incidences  of  endocarditis-
elated  bacteria  from  blood  draws  were  23,  33  and  60%  for
he  tooth  brushing,  extraction-amoxicillin  and  extraction-
lacebo  groups,  respectively  (P  <  0.0001).  Culture  positivity
as  lower  in  patients  receiving  amoxicillin.  The  authors  con-
luded  that  the  23%  positive  cultures  after  tooth  brushing
nd  the  high  frequency  of  oral  hygiene  activities  might  make
ooth  brushing  the  highest  at-risk  circumstance  for  IE.
nanswered questions and concerns
wing  to  lack  of  evidence,  all  the  recent  recommendations
re  class  IIa  and  level  of  evidence  B  or  C.  Given  that  no  ran-
omized,  controlled  study  is  currently  available,  the  level
f  evidence  for  these  new  recommendations  is  not  stronger
han  before.
nderlying congenital heart disease (CHD)
ative,  unrepaired  CHDs,  such  as  left-to-right  high-velocity
hunts  or  mild  mitral  and/or  aortic  valvulopathies,  are  no
onger  targets  for  IE  prophylaxis.  Nevertheless,  IE  can  occur
n  patients  with  such  underlying  CHD,  as  widely  reported  in
he  literature.  Knirsch  and  Nadal  reviewed  the  clinical  entity
f  CHD  associated  IE  between  1960  and  2007,  considering
eports  of  more  than  25  IE  cases,  and  provided  information
n  the  cardiac  diagnoses  and  procedures  performed.
VSD  is  the  most  frequent  unrepaired  CHD  associated  with
E  [25]. It  accounted  for  30%  of  cases  in  our  experience  of
E  in  CHD  [2].  Most  of  these  cases  were  small,  haemody-
amically  non-signiﬁcant  VSD  and/or  associated  with  aortic
egurgitation.  The  incidence  of  IE  in  unrepaired  VSD  is
.5—2.4  per  1000  patient-years.  The  natural  history  of  VSD
hows  that  the  estimated  lifetime  risk  for  IE  is  9.7%  at  age
0  years  and  12%  by  the  end  of  life  [26].
Bicuspidia  of  the  aortic  valve  has  long  been  considered
n  at-risk  CHD.  The  prevalence  of  this  anomaly  is  0.5—2%.
ortic  valve  bicuspidia  may  complicate  over  time  with  aortic
tenosis  and  mostly  aortic  insufﬁciency.  Recent  estimates  of
E  in  aortic  bicuspidia  are  around  0.3—2%  per  year  [27].
Isolated  PDA  frequency  is  about  1  in  2000  full-term
nfants.  Most  patients  are  asymptomatic  and  the  left-to-
ight  shunt  is  usually  non-signiﬁcant  [28]. However,  common
ractice  has  long  recommended  closure  of  PDA  because  of  a
ifetime  risk  of  IE.  Percutaneous  closure  of  PDA  has  become
he  leading  therapeutic  option  for  infants  and  children  with
aemodynamically  non-signiﬁcant  PDA.
Patients  with  MVP  have  a  threefold  to  eightfold  higher
isk  of  developing  IE,  with  an  estimated  incidence  of  about
.02%  per  year,  but  only  in  those  with  an  additional  mitral
egurgitation  [29]. Endocarditis  occurs  in  MVP  at  a rate  of
.1  cases  per  100  patient-years  [30].
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With the  improved  resolution  and  sensitivity  of  newer
enerations  of  echocardiograms,  clinicians  often  face  the
ilemma  of  the  patient  with  MVP  and  ‘trivial’  or  ‘minimal’
itral  regurgitation,  making  the  decision  to  apply  preven-
ion  of  IE  a  matter  of  debate.  Recent  criteria  from  the
HA  guidelines  may  help  with  this  decision,  as  valve  pro-
apse  of  2  mm  or  more  above  the  mitral  annulus  is  required
or  diagnosis  [31]. This  change  has  effectively  lowered  the
revalence  of  MVP  from  4—8%  of  the  general  population  to
—3%.
The  recent  guidelines  for  prevention  of  IE  published  by
he  AHA  in  2007  [13]  no  longer  consider  native  unrepaired
ardiac  lesions  to  be  at-risk  of  IE.  In  particular,  prophylaxis
s  no  longer  recommended  in  patients  with  MVP,  bicuspidia,
DA  or  VSD.  Nevertheless,  IE  can  occur  in  these  patients  and
s  reported  in  all  published  series.  This  discrepancy  probably
ontributes  to  clinicians  being  concerned  about  whether  to
ollow  these  guidelines  fully  or  not;  some  would  continue
revention  in  patients  they  feel  to  be  at  signiﬁcant  risk.
rocedures
treptococcus  and  Staphylococcus  are  the  two  main  micro-
ial  agents  responsible  for  IE  in  CHD,  coming  from  either
he  oral  cavity  or  the  skin.  Daily  buccal  activities  are
onsidered  as  the  current  leading  causes  of  bacteraemia.
owever,  this  concept  of  cumulative  bacteraemia  has  not
een  currently  supported  by  an  experimental  study  show-
ng  the  magnitude  that  everyday  bacteraemia  can  reach  and
hether  it  exceeds  the  theoretical  bacterial  inoculum  vol-
me  cut-off  needed  to  induce  IE.  It  is  also  unclear  if  repeat
veryday  bacteraemia  would  promptly  clear  from  the  body
r  would  induce  a  cumulative  level  of  circulating  micro-
ial  agents.  Moreover,  no  mention  is  provided  about  the
acterial  virulence  that  would  lessen  the  threshold  of  at-
isk  bacteraemia  or  about  the  immunosuppressive  status  of
he  patient.
It  is  commonly  recognized  that  the  skin  may  be  widely
olonized  by  commensal  but  also  pathogenic  Staphylococ-
us  agents  [32]. Any  cutaneous  damage,  including  tattooing
r  body  piercing,  may  therefore  induce  bacteraemia,  even
n  the  absence  of  proven  tissue  infection.  The  level  of  cuta-
eous  risk  might  be  underestimated  by  the  new  guidelines,
egarding  the  frequency  of  Staphylococcus  IE.
linicians’ behaviour
aced  with  these  new  recommendations,  Pharis  et  al.
ssessed  the  impact  of  the  2007  AHA  IE  prophylaxis
uidelines  on  clinician  practice  in  a  multicentre,  cross-
ectional,  web-based  survey  sent  to  Canadian,  Australian,
ew  Zealand  and  American  paediatric  and  adult  CHD  cardiol-
gists  in  2008  [33]. The  response  rate  was  55%.  Cardiologists
ere  divided  between  recommending  versus  not  recom-
ending  prophylaxis  for  perimembranous  VSD  status  after
urgical  patch  closure  with  no  residual  shunt,  3  months
ostoperatively.
The  greatest  proportion  of  circumstances  in  which  cardi-
logists  discontinued  prophylaxis  were  ‘small  muscular  VSD,
o  previous  endocarditis’  and  ‘small  audible  patent  ductus
rteriosus’.  Twenty-eight  percent  of  the  clinicians  felt  that
he  new  guidelines  left  some  patients  at-risk.  Therefore,
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[Infective  endocarditis  prophylaxis  in  congenital  heart  diseas
although  the  2007  guidelines  have  resulted  in  changes  in  IE
prophylaxis,  wide  heterogeneity  has  been  observed  among
the  cardiologists  who  are  in  charge  of  these  patients.  These
results  show  that  many  of  them  feel  concerned  about  the
safety  of  these  recommendations,  given  the  severity  and
life-threatening  risk  of  IE.
As  claimed  by  Weaver  et  al.,  ‘lack  of  evidence  is  not  nec-
essarily  equivalent  to  lack  of  beneﬁt’  and  ‘if  prophylaxis  is
futile,  why  select  high-risk  patients  for  prophylaxis?’  [34].
Protocols for antibiotic prophylaxis
According  to  he  current  recommended  protocols  for  antibi-
otic  prophylaxis,  an  oral,  single  dose  of  antibiotic  should  be
administered  30—60  minutes  before  the  invasive  procedure,
only  in  patients  in  the  high-risk  group  and  for  dental  at-risk
procedures.  If  the  dose  cannot  be  given  before,  it  should
be  done  within  2  hours  following  the  procedure  [32]. First-
line  antibiotics  are  focused  on  Streptococcus  infection  and
amoxicillin  is  the  recommended  ﬁrst-option  therapy.  In  case
of  allergy,  a  macrolide  should  be  chosen.  For  speciﬁc,  skin-
related  procedures,  the  regimen  should  mostly  focus  against
the  Staphylococcus  aureus  microbial  agent.  Severe  anaphy-
lactic  events  have  not  been  reported,  nor  have  single  doses
of  antibiotics  induced  resistance.
These  are  the  current  published  recommendations  for
antibiotic  prophylaxis:
• if the  patient  is  able  to  take  oral  medications,  amoxicillin
is  the  ﬁrst-line  antibiotic  and  should  be  administered  at  a
single  dose  of  50  mg/kg  in  children  (30—60  minutes  before
procedure)  or  2  g  in  adults;
• if  the  patient  is  unable  to  take  oral  medications,  intra-
venously  or  intramuscular  administration  of  antibiotic  is
required,  with  either  ampicillin  (50  mg/kg  in  children,  2  g
in  adults)  or  cefazolin  (or  ceftriaxone)  (50  mg/kg  in  chil-
dren,  1  g  in  adults);
• if  the  patient  is  allergic  to  penicillin  or  ampicillin  and
able  to  take  oral  medications,  penicillin  is  replaced  by
either  cephalexin  (50  mg/kg  in  children,  2  g  in  adults)
or  clindamycin  (20  mg/kg  in  children,  600  mg  in  adults)
or  azithromycin  or  clarithromycin  (15  mg/kg  in  children,
500  mg  in  adults);
• the  patient  is  allergic  to  penicillin  or  ampicillin,  but
unable  to  take  oral  medications,  intravenously  or  intra-
muscular  administration  of  antibiotic  is  required,  with
either  cefazolin  or  ceftriaxone  (50  mg/kg  in  children,  1  g
in  adults)  or  clindamycin  (20  mg/kg  in  children,  600  mg  in
adults).
Conclusion
The  incidence  and  severity  of  IE  has  not  decreased  signi-
ﬁcantly  over  the  years.  CHDs  are  speciﬁcally  exposed  to
IE  risk.  According  to  recent  revised  guidelines,  some  unre-
paired  native  congenital  heart  defects  are  no  longer  targets
for  IE  prophylaxis.  Recommendations  emphasize  daily  oral
activities  and  poor  buccal  and  skin  hygiene  as  the  leading
causes  of  IE.  These  substantial  changes  in  IE  prophylaxis  for
paediatric  and  adult  CHD  patients  raise  unanswered  ques-
tions  for  cardiologists  about  who  should  and  when  to  apply
[459
rophylaxis.  Further  studies  are  required  to  elucidate  and
ssess  the  consequences  and  impact  of  the  new  guidelines
n  CHD  patient  outcomes.
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